IDXG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IDXG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interpace Biosciences's gross profit for the three months ended in Sep. 2024 was $7.51 Mil. Interpace Biosciences's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $27.14 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Interpace Biosciences's gross profit for the three months ended in Sep. 2024 was $7.51 Mil. Interpace Biosciences's Revenue for the three months ended in Sep. 2024 was $12.30 Mil. Therefore, Interpace Biosciences's Gross Margin % for the quarter that ended in Sep. 2024 was 61.05%.
Interpace Biosciences had a gross margin of 61.05% for the quarter that ended in Sep. 2024 => Durable competitive advantage
During the past 13 years, the highest Gross Margin % of Interpace Biosciences was 60.46%. The lowest was 13.98%. And the median was 51.34%.
The historical data trend for Interpace Biosciences's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
8.33 | 10.73 | 18.80 | 18.23 | 23.90 |
Interpace Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
4.95 | 6.14 | 6.07 | 7.43 | 7.51 |
For the Diagnostics & Research subindustry, Interpace Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Interpace Biosciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit (A: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 40.214 | - | 16.31 | |
= | 23.90 |
Interpace Biosciences's Gross Profit for the quarter that ended in Sep. 2024 is calculated as
Gross Profit (Q: Sep. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 12.295 | - | 4.789 | |
= | 7.51 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.14 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Interpace Biosciences's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as
Gross Margin % (Q: Sep. 2024 ) | = | Gross Profit (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 7.51 | / | 12.295 | |
= | 61.05 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Interpace Biosciences (OTCPK:IDXG) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Interpace Biosciences had a gross margin of 61.05% for the quarter that ended in Sep. 2024 => Durable competitive advantage
Thank you for viewing the detailed overview of Interpace Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Mccarthy | officer: Principal Financial Officer | C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054 |
Vijay Aggarwal | director | 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405 |
Thomas W. Burnell | director, officer: President and CEO | 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309 |
Peter H Kamin | 10 percent owner | 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410 |
Fred S. Knechtel | officer: Chief Financial Officer | REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064 |
Fortunato R. Rocca | director | C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081 |
Edward Chan | director | C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104 |
1315 Capital Ii, L.p. | 10 percent owner | 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104 |
Robert J. Gorman | director | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Laurence Mccarthy | director | 2110 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Ampersand 2018 Limited Partnership | 10 percent owner | 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481 |
Eric B. Lev | director, 10 percent owner | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Thomas John Freeburg | officer: Chief Accounting Officer | INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054 |
Gregory Richard | officer: Chief Commerical Officer | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054 |
Felice Schnoll-sussman | director | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054 |
From GuruFocus
By Marketwired • 10-15-2024
By sperokesalga sperokesalga • 05-12-2023
By Value_Insider Value_Insider • 10-20-2022
By GuruFocus Research • 02-13-2024
By Marketwired • 08-01-2024
By Marketwired • 07-29-2024
By GuruFocus Research • 02-13-2024
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 11-04-2024
By GuruFocusNews GuruFocusNews • 07-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.